Modeling the impact of peginterferon alfa-2a (40KD) (Pegasys®) plus ribavirin therapy on life expectancy and medical care costs in chronic hepatitis C.

被引：0
|
作者：
Jensen, CDM
Bernstein, DE
Hassanein, TI
Foster, GR
Lee, SS
Cheinquer, H
Craxi, A
Cooksley, WGE
Klaskala, W
Green, J
机构：
[1] Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA
[2] N Shore Univ Hosp, Manhasset, NY USA
[3] Univ Calif San Diego, San Diego, CA 92103 USA
[4] Univ London Imperial Coll Sci Technol & Med, London, England
[5] Univ Calgary, Calgary, AB, Canada
[6] Univ Fed Rio Grande Sul, Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil
[7] Inst Clin Med Policlin, Palermo, Italy
[8] Royal Brisbane Hosp, Brisbane, Qld 4029, Australia
[9] Hoffmann La Roche Inc, Nutley, NJ 07110 USA
来源：
HEPATOLOGY | 2002年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1761
引用
收藏
页码：603A / 603A
页数：1
相关论文
共 50 条
  • [21] Predictors of virologic relapse in patients with chronic hepatitis C (CHC) treated with peginterferon alfa-2a (40KD) (pegasys) alone or in combination with ribavirin (copegus)
    Balan, V
    Zeuzem, S
    Sette, H
    Fried, M
    Jensen, D
    Pastore, G
    Marcellin, P
    Sedarati, F
    JOURNAL OF HEPATOLOGY, 2003, 38 : 19 - 19
  • [22] PEG-IFN alfa-2a (40KD) (Pegasys) plus amantadine (AMA) or ribavirin (RBV) in naive patients with chronic hepatitis C
    Ideo, G
    Giuseppe, S
    Attili, A
    Chirianni, A
    Craxi, A
    Di Perri, G
    Picciotto, A
    Rizzetto, M
    Ruggiero, G
    Suter, F
    Sarracino, M
    HEPATOLOGY, 2002, 36 (04) : 570A - 570A
  • [23] Cost-effectiveness of first-line peginterferon alfa-2a (40KD) (Pegasys®) plus ribavirin (Copegus®) in patients with mild chronic hepatitis C (cHC) in the US
    El-Serag, Hashem B.
    Patel, Kavita K.
    Wintfeld, Neil
    Green, Jesse
    Sullivan, Sean D.
    GASTROENTEROLOGY, 2006, 130 (04) : A837 - A837
  • [24] PREDICTIVE FACTORS OF THROMBOCYTOPENIA IN TREATMENT OF CHRONIC HEPATITIS C (CHC) PATIENTS WITH PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN
    Mauss, S.
    Schober, A.
    Lutz, T.
    Moog, G.
    Schuchmann, M.
    Heyne, R.
    John, C.
    Schiffelholz, W.
    Baumgarten, A.
    Hey, K. -H.
    Eisenbach, C.
    Teuber, G.
    Schmidt, W.
    Bruch, H. -R.
    Geyer, P.
    Alshuth, U.
    Hueppe, D.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S185 - S185
  • [25] Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin
    Foster, Graham R.
    Fried, Michael W.
    Hadziyannis, Stephanos J.
    Messinger, Diethelm
    Freivogel, Klaus
    Weiland, Ola
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2007, 42 (02) : 247 - 255
  • [26] Predictive Factors of Thrombocytopenia in Treatment of Chronic Hepatitis C (CHC) Patients With Peginterferon Alfa-2a (40KD) and Ribavirin
    Mauss, Stefan
    Schober, Andreas
    Lutz, Thomas
    Moog, Gero
    Schuchmann, Marcus
    Heyne, Renate
    John, Christine
    Schiffelholz, Willibold
    Baumgarten, Axel
    Hey, Karl-Heinz
    Eisenbach, Christoph
    Teuber, Gerlinde
    Schmidt, Wolfgang
    Bruch, Harald-Robert
    Geyer, Peter
    Alshuth, Ulrich
    Hueppe, Dietrich
    GASTROENTEROLOGY, 2011, 140 (05) : S948 - S948
  • [27] Peginterferon alfa-2a (40KD) (pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa-2a (roferon-A) plus RBV and AMA in IFN/RBV nonresponder patients with chronic hepatitis C (CHC)
    Fargion, S
    Borzio, M
    Cargnel, A
    JOURNAL OF HEPATOLOGY, 2003, 38 : 139 - 140
  • [28] Pharmacokinetics of peginterferon ALFA-2A (40KD, PEGASYS) compared to peginterferon ALFA-2B (12KD, pegintron) in naive patients with chronic hepatitis C (CHC)
    Bruno, R
    Sacchi, P
    Ciappina, V
    Maffezzini, E
    Patruno, SFA
    Zocchetti, C
    Filice, G
    JOURNAL OF HEPATOLOGY, 2003, 38 : 129 - 130
  • [29] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C
    Rakov, NE
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (03): : 259 - 260
  • [30] Peginterferon alfa-2a (40 KD) (pegasys) plus ribavirin (copegus) is an efficacious and safe treatment for chronic hepatitis C (CHC) in patients with compensated cirrhosis
    Marcellin, P
    Brillanti, S
    Cheinquer, H
    Cooksley, WGE
    Shiffman, L
    Schmidt, WE
    Brunda, M
    JOURNAL OF HEPATOLOGY, 2003, 38 : 154 - 154
12345